PPARG and cancer: These authors demonstrated inhibition of cancer cell proliferation and function as NR ligands with DIM-Ph-CF3 being an NR4A1 [14] and PPARγ [15–17, 20] agonist, and DIM-Ph-4-OMe a selective NR4A1 agonist [14].